Paradigm Biopharmaceuticals stock forecast
Want to see AU:PAR full AI Analyst Report?
Paradigm Biopharmaceuticals (PAR) Share Forecast & Price Target
PAR Analyst Ratings
PAR Stock 12 Month Forecast
Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| John Hester | Bell Potter | AU$0.45→AU$0.42 | buy | 71.43%Upside | Reiterated | 08/03/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| John HesterBell Potter | BuyReiteratedAU$0.45→AU$0.42 | 08/03/26 | 71.43%Upside |
Best Analysts Covering Paradigm Biopharmaceuticals
Copying John Hester's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +4.94% per trade.
Copying John Hester's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -38.92% per trade.
Copying John Hester's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -75.85% per trade.
PAR Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 2 | 1 | 1 | 0 |
In the current month, PAR has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PAR average Analyst price target in the past 3 months is ―.
PAR Financial Forecast
PAR Earnings Forecast
Next quarter’s earnings estimate for PAR is -AUD 0.10 with a range of ― to ―. The previous quarter’s EPS was -AUD 0.10. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
PAR Sales Forecast
Next quarter’s sales forecast for PAR is AUD 55.00K with a range of ― to ―. The previous quarter’s sales results were AUD 55.00K. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

